Long-term CAR-T Persistence Linked to Myeloma Treatment Outcomes

Researchers examined 102 patients who initially achieved minimal residual disease (MRD) negativity following treatment with equecabtagene autoleucel. The findings establish a clear correlation between the persistence of CAR-T cells—measured by vector copy number in peripheral blood—and the duration of MRD negativity. Patients who maintained sustained MRD-negative status exhibited a median cell persistence of 463 days, compared to 272 days for those who experienced MRD conversion.

High-risk indicators, including del(17p) genetic mutations, elevated tumor burden, and rapid disease progression, were more prevalent in the group that saw early CAR-T cell clearance. Professor Lugui Qiu noted that while MRD negativity remains a critical clinical milestone, these findings offer a potential pharmacodynamic marker for long-term disease management. The study suggests that strategies to enhance cell longevity could be pivotal for improving patient outcomes, particularly when considering the application of CAR-T therapy in earlier lines of treatment.